Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
While the Ramachandran plot has been a textbook resource for explaining the structural behavior of peptide bond, an exhaustive exploration of how a peptide behaves in every region of the Ramachandran plot was only recently published (Mannige 2017). The Molecular Biophysics Unit at Indian Institute of Science celebrated 50 years of Ramachandran Map by organizing International Conference on Biomolecular Forms and Functions from 8–11 January 2013.
In 2025, despite freezing cold, hundreds of customers started lining up outside the restaurant as early as five in the morning in Cambridge, Ontario. Later that year, construction of a second London location on Richmond Street across from Masonville Mall was completed in September.
The pepper plant is a perennial woody vine growing up to 4 m (13 ft) in height on supporting trees, poles, or trellises. It is a spreading vine, rooting readily where trailing stems touch the ground. The leaves are alternate, entire, 5 to 10 cm (2 to 4 in) long and 3 to 6 cm (1 to 2+1⁄2 in) across.
On 30 August 2023, Health Secretary Steve Barclay announced that it would be upgraded to a statutory inquiry, enabling witnesses to be compelled to give evidence. The inquiry, chaired by Lady Justice Thirlwall, formally opened on 22 November 2023. The public hearings began on 10 September 2024. In a ruling on 29 May 2024, the chair determined that remote live viewing would be available to Core Participants, their legal representatives and the media, but not to the wider public. During the hearings, colleagues gave evidence describing Letby as "excited and gossipy" when discussing the death of an infant, saying she preferred caring for unwell babies, complained when moved to less acute areas, and expressed eagerness for the first death of an infant to "get it out of the way". Former Health Secretary Jeremy Hunt apologised to families during the 2025 hearings, saying the government had taken "too long" to act. Letby's lawyers and other supporters later asked for the inquiry to be paused while her application to the Criminal Cases Review Commission was considered. Thirlwall rejected the request in March 2025 and said she intended to deliver her report in November 2025. In April 2026, the inquiry said that work on the report was still ongoing and that a publication date could not be confirmed.
Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in turn can be caused by a number of problems. Some forms of cancer can cause SIADH, particularly small cell lung carcinoma but also a number of other tumors. A variety of diseases affecting the brain or the lung (infections, bleeding) can be the driver behind SIADH. A number of drugs have been associated with SIADH, such as certain antidepressants (serotonin reuptake inhibitors and tricyclic antidepressants), the anticonvulsant carbamazepine, oxytocin (used to induce and stimulate labor), and the chemotherapy drug vincristine. It has also been associated with fluoroquinolones (including ciprofloxacin and moxifloxacin). Finally, it can occur without a clear explanation. Hyponatremia can be treated pharmaceutically through the use of vasopressin receptor antagonists.
Sources: en.wikipedia.org
== General and cited references == Gabriele Froböse, Rolf Froböse, Michael Gross (Translator): Lust and Love: Is It More than Chemistry? Royal Society of Chemistry, 2006; ISBN 0-85404-867-7. Michael Scott: Pillow Talk: A Comprehensive Guide to Erotic Hypnosis and Relyfe Programming. Blue Deck Press, 2011; ISBN 0-98341-640-0.
During this initial stage, when methane is relatively abundant, dense mussel beds also form near the cold seep. Mostly composed of species in the genus Bathymodiolus, these mussels are primarily nourished by symbiotic bacteria that also produce energy from methane, similar to their relatives that form mats. Bathymodiolin mussels often supplement this nutrition source by filter feeding on particulate organic matter known as marine snow. Chemosynthetic bivalves are prominent constituents of the fauna of cold seeps and are represented in that setting by five families: Solemyidae, Lucinidae, Vesicomyidae, Thyasiridae, and Mytilidae. This microbial activity produces calcium carbonate, which is deposited on the seafloor and forms a layer of rock. During a period lasting up to several decades, these rock formations attract siboglinid tubeworms, which settle and grow along with the mussels. Like the mussels, tubeworms rely on chemosynthetic bacteria (in this case, a type that needs hydrogen sulfide instead of methane) for survival. True to any symbiotic relationship, a tubeworm also provides for its bacteria by appropriating hydrogen sulfide from the environment. The sulfide not only comes from the water, but is also mined from the sediment through an extensive "root" system that a tubeworm "bush" establishes in the hard, carbonate substrate. A tubeworm bush can contain hundreds of individual worms, which can grow a meter or more above the sediment. Cold seeps do not last indefinitely.
People with early keratoconus often notice a minor blurring or distortion of their vision, as well as an increased sensitivity to light, so they may visit their clinician seeking corrective lenses for reading or driving. At early stages, the symptoms of keratoconus may be no different from those of any other refractive defect of the eye. As the disease progresses, vision deteriorates, sometimes rapidly due to irregular astigmatism. Visual acuity becomes impaired at all distances, and night vision is often poor. Some individuals have vision in one eye that is markedly worse than the other eye. The disease is often bilateral though asymmetrical. Some develop photophobia (sensitivity to bright light), eye strain from squinting in order to read, or itching in the eye, but there is normally little or no sensation of pain. It may cause luminous objects to appear as cylindrical pipes with the same intensity at all points.
=== Tissue preparation === The tissue samples must be preserved quickly in order to reduce molecular degradation. The first step is to freeze the sample by wrapping the sample then submerging it in a cryogenic solution. Once frozen, the samples can be stored below -80 °C for up to a year. When ready to be analyzed, the tissue is embedded in a gelatin media which supports the tissue while it is being cut, while reducing contamination that is seen in optimal cutting temperature compound (OCT) techniques. The mounted tissue section thickness varies depending on the tissue. Tissue sections can then be thaw-mounted by placing the sample on the surface of a conductive slide that is of the same temperature, and then slowly warmed from below. The section can also be adhered to the surface of a warm slide by slowly lowering the slide over the cold sample until the sample sticks to the surface. The sample can then be stained in order to easily target areas of interest, and pretreated with washing in order to remove species that suppress molecules of interest. Washing with varying grades of ethanol removes lipids in tissues that have a high lipid concentration with little delocalization and maintains the integrity of the peptide spatial arrangement within the sample.
Douglas Carlyle Cameron (born March 22, 1957) is an American engineer, inventor, and investor. He is a senior managing director for the U.S.-China Green Fund. He is on the board of the Foundation for Food and Agriculture Research (FFAR) and is a technical and business advisor to organizations including the VTT (Finland), and the Center for Bioenergy Innovation (USA).
Sources: en.wikipedia.org
=== In electronics / electricity === PVDF is commonly used as insulation on electrical wires, because of its combination of flexibility, low weight, low thermal conductivity, high chemical corrosion resistance, and heat resistance. Most of the narrow 30-gauge wire used in wire wrap circuit assembly and printed circuit board rework is PVDF-insulated. In this use the wire is generally referred to as "Kynar wire", from the trade name. The piezoelectric properties of PVDF are exploited in the manufacture of tactile sensor arrays, inexpensive strain gauges, and lightweight audio transducers. Piezoelectric panels made of PVDF are used on the Venetia Burney Student Dust Counter, a scientific instrument of the New Horizons space probe that measures dust density in the outer Solar System. PVDF is the standard binder material used in the production of composite electrodes for lithium-ion batteries. Solution of PVDF 1−2% by mass in N-methyl-2-pyrrolidone (NMP) is mixed with an active lithium storage material such as graphite, silicon, tin, LiCoO2, LiMn2O4, or LiFePO4 and a conductive additive such as carbon black or carbon nanofibers. This slurry is cast onto a metallic current collector, and the NMP is evaporated to form a composite or paste electrode. PVDF is used because it is chemically inert over the potential range used and does not react with the electrolyte or lithium.
For services to Social Enterprise and the Creative Industries. Ivora Maria Ferreria-Bean. Team Manager, Birmingham Children's Trust. For services to Children and Families. Malcolm Ernest Ferris-Lay. Trustee, Tea Trade Benevolent Society and Scottish Tartan Authority. For Charitable Service. Maxine Jane Ficarra (Maxine Purdie). Lately Chief Executive Officer, PraxisAuril. For services to Knowledge Exchange. Margaret Ruth Fingerhut. For services to Music and to Charitable Fundraising. David Edward Clarke Finlay. For services to Olympic Wrestling in Northern Ireland. Stephen Fischbacher. Founding Director, Fischy Music. For services to Mental Health and Well-Being. Alison Fordy. Proprietor, Alison Radcliffe School of Dance. For services to Young People and to the community in Middlesbrough, North Yorkshire. Alison Fotheringham. Appeals and Litigation Assistant Director, Home Office. For Public and Voluntary Service. Alison Jane France. Operational Leader, Department for Work and Pensions. For services to Disadvantaged People. Susan Elizabeth Francis. Principal Educational Psychologist and Strategic Lead for Children and Young People's Emotional Wellbeing and Mental Health, Enfield London Borough Council. For services to Children with Special Educational Needs and Disabilities. Mike Anthony Frankl. For services to Charity, to Homeless People and to the Jewish Community in Cambridge. Pamela Marguerita Frickleton. Foster Carer, Plymouth City Council. For services to Young People. Peter Thornton Frickleton. Foster Carer, Plymouth City Council. For services to Young People.
== Volunteers == CLSI relies on more than 2,000 volunteers. Volunteers and mentors also collaborate with CLSI's Global Health Partnerships to help establish laboratory quality management systems in resource-limited countries.
== Career == At the institute, later Rockefeller University, he worked as an Assistant for Dr. D.W. Woolley on a dinucleotide growth factor he discovered in graduate school and on peptide growth factors that Woolley had discovered earlier. These studies led to the need for peptide synthesis and, eventually, to the idea for solid phase peptide synthesis (SPPS) in 1959. In 1963, he was sole author of a classic paper in the Journal of the American Chemical Society in which he reported a method he called "solid phase peptide synthesis". This article is the fifth most cited paper in the journal's history. In the mid-60s Dr. Merrifield's laboratory first synthesized bradykinin, angiotensin, desamino-oxytocin and insulin. In 1969, he and his colleague Bernd Gutte announced the first synthesis of the enzyme ribonuclease A. This work proved the chemical nature of enzymes. Dr. Merrifield's method greatly stimulated progress in biochemistry, pharmacology and medicine, making possible the systematic exploration of the structural basis of the activities of enzymes, hormones and antibodies. The development and applications of the technique continued to occupy his laboratory, where he remained active at the bench until recently. In 1993, Jeffrey I. Seeman published Life during a Golden Age of Peptide Chemistry, Merrifield's autobiography, in the series "Profiles, Pathways, and Dreams" for the American Chemical Society. He received the Association of Biomolecular Resource Facilities Award for outstanding contributions to Biomolecular Technologies in 1998.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.